C-EHEVSIRT6 activation, small molecules, neuroprotection
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop the CL5D small-molecule series within Galilei's SIRT6 activator pipeline.
Small-molecule SIRT6 activator series development.
Listed in the supplied pipeline as the CL5D series.
Develop proprietary MDL-derived SIRT6 activator analogs for Galilei's small-molecule SIRT6 activator pipeline.
Small-molecule medicinal chemistry around MDL SIRT6 activator analogs.
Listed in the supplied pipeline as proprietary MDL analogs.
A listed 2022 publication reports MDL-800 suppresses inflammation via NF-kB and promotes angiogenesis in mouse wound healing, but the supplied material does not state Galilei generated those results.
Develop a proprietary stabilized analog of the SIRT6 activator RM-13 as part of Galilei's SIRT6 activator pipeline.
Small-molecule analog development targeting SIRT6 activation.
Listed in the supplied pipeline as a proprietary, stabilized RM-13 analog.
Advance the CL5D series as part of Galilei's proprietary SIRT6 activator pipeline.
Small-molecule SIRT6 activator series development.
Listed in the supplied pipeline as the CL5D series.
Develop proprietary analogs based on MDL-class SIRT6 activators for age-related disease applications.
Small-molecule SIRT6 activator analog development.
Listed in the supplied pipeline as proprietary MDL analogs.
A listed 2022 publication reports MDL-800, a SIRT6 activator, suppressed inflammation via the NF-kB pathway and promoted angiogenesis in a mouse wound-healing model.
Develop a proprietary small-molecule SIRT6 activator for neuroprotection in glaucoma, with potential relevance to other age-related diseases.
Small-molecule SIRT6 activation; medicinal chemistry, ADME/PK optimization, in vivo proof of concept, and development-candidate nomination.
Development plan focuses on medicinal chemistry, ADME/PK optimization, in vivo proof of concept, and development-candidate nomination for glaucoma.
Supplied material states SIRT6 activation has shown neuroprotective, anti-inflammatory, mitochondrial, metabolic, and DNA-repair effects; a listed 2024 publication reports Sirt6 protection of retinal ganglion cells and optic nerve during aging and glaucoma.
Develop proprietary stabilized analogs of the SIRT6 activator RM-13 as part of Galilei's SIRT6 activator pipeline.
Small-molecule analog design and optimization targeting SIRT6 activation.
Listed in the supplied pipeline as a proprietary, stabilized RM-13 analog.